Compare OBT & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | ASMB |
|---|---|---|
| Founded | 1892 | 2005 |
| Country | United States | United States |
| Employees | 225 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.5M | 440.0M |
| IPO Year | 2021 | 2010 |
| Metric | OBT | ASMB |
|---|---|---|
| Price | $30.88 | $28.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $36.00 | ★ $43.40 |
| AVG Volume (30 Days) | 48.8K | ★ 94.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 2.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.27 | $33.33 |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.97 | $7.76 |
| 52 Week High | $37.99 | $39.71 |
| Indicator | OBT | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 46.78 |
| Support Level | $29.33 | $26.50 |
| Resistance Level | $31.49 | $30.66 |
| Average True Range (ATR) | 1.12 | 1.42 |
| MACD | -0.45 | -0.03 |
| Stochastic Oscillator | 24.76 | 27.35 |
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.